Lenz Therapeutics is under investigation by Pomerantz LLP for potential securities fraud following disappointing Q2 2026 results. The company reported $5.5 million in revenue, largely from one-time licensing deals, with its main eye drop product, VIZZ, showing minimal sales growth. This led Bank of America to downgrade Lenz's stock and cut its price target, causing a sharp stock price drop and investor losses. The investigation aims to determine if Lenz and its executives engaged in unlawful practices affecting shareholders.
RH is set to report Q2 2026 earnings facing challenges from a weak housing market and international expansion expenses. Analysts expect earnings per share to fall significantly to between $0.38 and $0.46, down from $2.93 last year, despite a slight r...
Chewy reported Q2 results largely in line with expectations, with net sales up 7.3% to $3.33 billion and adjusted earnings matching forecasts at $0.36 per share. However, shares fell 10.8% due to concerns about slowing organic growth, cautious consum...
Macy's reported Q1 earnings per share of $0.40, exceeding the $0.37 estimate, with revenue of $4.87 billion beating expectations. Growth was driven by strong sales in Bloomingdale's, Bluemercury, and Macy's stores. The company raised its full-year ne...
Tyson Foods faces operational challenges, especially in its beef segment, leading Piper Sandler to cut its price target from $78 to $66. The company lowered its 2026 revenue growth forecast to 1.5%-2% and expects a beef segment operating loss between...
Descartes Systems Group is set to release its Q2 2027 earnings with analysts expecting $0.57 EPS and $197.54 million revenue. The company recently acquired Extensiv for $120 million, enhancing its warehouse and fulfillment solutions for e-commerce an...
